These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25132750)

  • 1. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.
    Molina-Infante J; Gisbert JP
    World J Gastroenterol; 2014 Aug; 20(30):10338-47. PubMed ID: 25132750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era.
    Georgopoulos SD; Papastergiou V; Karatapanis S
    Expert Opin Pharmacother; 2015; 16(15):2307-17. PubMed ID: 26330278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
    Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
    Marin AC; McNicholl AG; Gisbert JP
    Expert Opin Pharmacother; 2013 May; 14(7):843-61. PubMed ID: 23537368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori.
    Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2011 Sep; 34(6):604-17. PubMed ID: 21745241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Helicobacter pylori infection: a clinical practice update.
    Zagari RM; Frazzoni L; Marasco G; Fuccio L; Bazzoli F
    Minerva Med; 2021 Apr; 112(2):281-287. PubMed ID: 32700868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of second-line regimens for
    Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori eradication in West Asia: a review.
    Fakheri H; Bari Z; Aarabi M; Malekzadeh R
    World J Gastroenterol; 2014 Aug; 20(30):10355-67. PubMed ID: 25132752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of Helicobacter pylori infection: which regimen first?
    Federico A; Gravina AG; Miranda A; Loguercio C; Romano M
    World J Gastroenterol; 2014 Jan; 20(3):665-72. PubMed ID: 24574740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
    Venerito M; Krieger T; Ecker T; Leandro G; Malfertheiner P
    Digestion; 2013; 88(1):33-45. PubMed ID: 23880479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward population specific and personalized treatment of Helicobacter pylori infection.
    Liou JM; Chen PY; Kuo YT; Wu MS;
    J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failed Eradication for Helicobacter pylori. What Should Be Done?
    Mégraud F
    Dig Dis; 2016; 34(5):505-9. PubMed ID: 27332826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.